Clinical Research Directory

Inclusion Criteria: * Provision of signed and dated informed consent form * Stated willingness to comply with all study procedures and availability for the duration of the study * Receiving a first or second kidney transplant * Male or female, aged ≥18 to ≤65 * Women of child bearing potential who have a negative serum pregnancy test prior to treatment * Women of child bearing potential (including perimenopausal women who have had a menstrual period within the previous 1 year) who agree to use 2 forms of effective birth control regimen (at least one of which is a barrier method) throughout the study period and for 6 weeks following the end of the study or the last dose of mycophenolic acid, whichever comes first. * Panel of reactive antibodies \<50% * Able to take oral medication * Agreement to adhere to Lifestyle Considerations throughout study duration: refraining from the consumption of grapefruit or grapefruit juice and stopping any anticoagulation therapy, including ASA, one week prior and one week post kidney biopsy procedure Exclusion Criteria: * Transplantation of any organ other than kidney * History or presence of second degree AV block, third degree AV block, symptomatic bradycardia, or an arrhythmia requiring current treatment with Class Ia or III antiarrhythmic drugs. * Heart rate \<60 beats per minute * Presence of an increased QTc interval \> 500 ms on screening ECG. * Presence of a cardiac pacemaker. * History of any major cardiac events, including heart attack within the last six months of enrollment, unstable angina, congestive heart failure, or any severe cardiac disease as determined by investigator * Known macular degeneration * Diagnosed with any significant coagulopathy or medical condition requiring long-term systemic anticoagulation after transplantation, which would interfere with obtaining biopies. * Diagnosed with chronic immune system disease * Diagnosed with acute pulmonary disease * Diagnosed with severe liver disease, including abnormal liver enzymes or total bilirubin greater than three times upper limit of normal. * Diagnosed with any past or present malignancies except squamous or basal cell carcinoma of the skin excised at least two years prior to randomization. * Diagnosed with active acute or chronic infection, or febrile illness within two weeks prior to randomization. * Recent history of strokes in the preceding 6 months * Use of ketoconazole for more than 2 weeks * Use of any investigational drug during the 4 weeks prior to enrolling in this study * Women of child bearing potential who are breastfeeding * Women of childbearing potential not practicing reliable methods of contraception. Reliable methods for contraception include surgical sterilization (hysterectomy, bilateral tubal ligation), double-barrier method (such as condom and diaphragm). To be considered as post-menopausal and not of childbearing potential, female participants must have experienced 12 consecutive months of amenorrhea. * Known allergic reactions to components of Gilenya®, specifically fingolimod, gelatin, magnesium stearate, mannitol, titanium dioxide, and/or yellow iron oxide * Presence of any medical or psychosocial condition, which the investigator believes, would hinder adherence to the study requirements.